Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30322% above fair value

$29.04−0.44 (-1.49%)

Close on Nov 13, 2026Market cap $4.63BP/E –Yield –

Adaptive Biotechnologies EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Adaptive Biotechnologies has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Adaptive Biotechnologies's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADPT.

Revenue growth17.9% · median 51.3%

Gross margin74.2% · median 98.8%

Operating margin-16.2% · median -60.8%

Net margin-23.7% · median -59.6%

Advertisement
300 × 250

See a number that looks wrong?